Case-Population Studies in Pharmacoepidemiology-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Case-Population Studies in Pharmacoepidemiology

Published:2002 Issue:1 Volume:25 Page:7-19
ISSN:0114-5916
Container-title:Drug Safety
language:en
Short-container-title:Drug Safety

Author:

Capell?? Dolors,Pedr??s Consuelo,Vidal Xavier,Laporte Joan-Ramon

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pharmacology,Toxicology

Reference42 articles.

1. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: A regulatory perspective

2. Identification of adverse reactions to new drugs. II--How were 18 important adverse reactions discovered and with what delays?

3. Identification of adverse reactions to new drugs. II (continued): How were 18 important adverse reactions discovered and with what delays?

4. Identification of adverse reactions to new drugs. III: Alerting processes and early warning systems.

5. Spontaneous reporting of adverse drug reactions. I: the data.

Cited by 27 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Post-marketing safety concerns with montelukast: A pharmacovigilance study based on the FDA adverse event reporting system;Int. Journal of Clinical Pharmacology and Therapeutics;2024-08-05

2. Post-marketing safety concern of PI3K inhibitors in the cancer therapies: an 8-year disproportionality analysis from the FDA adverse event reporting system;Expert Opinion on Drug Safety;2024-07-31

3. Postmarketing Safety Concerns of Teprotumumab: A Real-World Pharmacovigilance Assessment;The Journal of Clinical Endocrinology & Metabolism;2024-06-15

4. Assessing safety concerns of interstitial lung disease associated with antibody-drug conjugates: a real-world pharmacovigilance evaluation of the FDA adverse event reporting system;International Journal of Clinical Pharmacy;2023-12-15

5. Assessing real-world safety concerns of Sacituzumab govitecan: a disproportionality analysis using spontaneous reports in the FDA adverse event reporting system;Frontiers in Oncology;2023-10-06

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3